Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IDE | P14735 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28073279 | 0.98 | COMT (0.46) | COMTLMNASMN1; SMN2NFE2L2ALDH1A1 | |
| SCHEMBL3698635 | 0.98 | COMT (0.46) | COMTLMNASMN1; SMN2NFE2L2ALDH1A1 | |
| SCHEMBL3713453 | 0.98 | COMT (0.46) | COMTLMNASMN1; SMN2NFE2L2ALDH1A1 | |
| SCHEMBL3698654 | 0.98 | COMT (0.46) | COMTLMNASMN1; SMN2NFE2L2ALDH1A1 | |
| Quinoline SCHEMBL27999776 | 0.87 | ALDH1A1 (0.53) | COMTNFE2L2ALDH1A1CYP1A2HIF1A | |
| Dimethylformamide SCHEMBL27642635 | 0.87 | NFE2L2 (0.41) | COMTLMNASMN1; SMN2NFE2L2ALDH1A1 | |
| SCHEMBL925929 | 0.83 | NFE2L2 (0.46) | LMNASMN1; SMN2NFE2L2ACLY | |
| SCHEMBL31634218 | 0.83 | NFE2L2 (0.46) | LMNASMN1; SMN2NFE2L2ACLY | |
| SCHEMBL349118 | 0.81 | TRPV4 (0.51) | LMNASMN1; SMN2NFE2L2ALDH1A1HSD17B10 | |
| SCHEMBL29435677 | 0.81 | TRPV4 (0.51) | LMNASMN1; SMN2NFE2L2ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | claimed |
| CN-103814021-B | Dihydroquinoline 2 ketone derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-21 | — | — | CN | claimed |
| CN-103517905-B | Novel hexahydropyrroloimidazolone compounds | 霍夫曼-拉罗奇有限公司 | 2016-08-24 | — | — | CN | claimed |
| EP-2707371-B1 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | claimed |
| CN-102083797-B | Tetrahydroisoquinolines, pharmaceutical compositions containing them and their use in therapy | ABBOTT GMBH & CO KG | 2014-06-04 | — | — | CN | claimed |
| CN-103814021-A | New dihydroquinoline-2-one derivatives | HOFFMANN LA ROCHE | 2014-05-21 | — | — | CN | claimed |
| EP-2707371-A1 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-03-19 | — | — | EP | claimed |
| CN-103517905-A | Novel hexahydropyrroloimidazolone compounds | HOFFMANN LA ROCHE | 2014-01-15 | — | — | CN | claimed |
| US-8497288-B2 | Hexahydropyrroloimidazolone compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-07-30 | — | — | US | claimed |
| CN-101945877-B | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2013-07-03 | — | — | CN | claimed |
| WO-2012152663-A1 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-15 | — | — | WO | claimed |
| US-20120289549-A1 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-15 | — | — | US | claimed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004069844-A1 | NOVEL TRICYCLIC OXAZEPINE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LES LABORATOIRES SERVIER (FR) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289549-A1 | NEW HEXAHYDROPYRROLOIMIDAZOLONE COMPOUNDS | LIPC, PNLIP, LIPE | COMT 3915/4885LMNA 1627/4885SMN1; SMN2 4851/4885 |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | COMT 1672/4885LMNA 542/4885SMN1; SMN2 14/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | COMT 1672/4885LMNA 542/4885SMN1; SMN2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.